NAD+ supplementation: what the science says about timing and effects

What did @projectbiohackedjeff actually say?

The creator's core argument is that standard subcutaneous NAD+ protocols, typically 25-75mg two to three times weekly, are too slow and too low. He wants people to dose daily and escalate quickly, mimicking the loading-dose approach used in IV clinics. He also flatly dismisses oral NAD+ precursors like NMN and NR as "garbage" and "hype," and argues that injectable or IV NAD+ is the only form that produces real results.

He frames this as a frustration with people giving up too soon, and positions rapid dose escalation as the fix. He also makes a specific claim that IV clinics use four to five infusions of 500mg as a loading protocol, and suggests subcutaneous users should replicate that logic. Throughout, he's careful to say he's not prescribing, but the practical effect of the advice is to push users toward higher, faster dosing without clinical supervision.

Does the science back this up?

Partially, but with important caveats. The IV loading-dose approach exists in clinical settings, but the direct translation to self-administered subcutaneous injections is not supported by published data. The claim that slow titration protocols are entirely "made up" is an overstatement.

There is legitimate research showing NAD+ levels decline with age. A 2023 review by Covarrubias et al. in Nature Metabolism confirmed age-related NAD+ depletion and linked it to mitochondrial dysfunction. The IV loading model he references is grounded in clinical addiction medicine, where high-dose NAD+ infusions have been used for decades, though the evidence base there is also limited and largely observational.

On NMN and NR, the picture is more nuanced than he lets on. A 2023 randomized controlled trial by Yi et al. in Nature Aging showed NMN supplementation did raise blood NAD+ levels in older adults and improved some muscle function metrics. That is not nothing. Dismissing all oral precursors as ineffective is not fully supported by current evidence, even if injectable forms likely produce larger acute increases.

The idea that subcutaneous NAD+ bioavailability mirrors IV is also unverified. No published pharmacokinetic head-to-head comparison between these routes appears in peer-reviewed literature as of this writing.

What did they get wrong (or right)?

He gets credit for pointing out that rigid, universal slow-titration protocols lack a strong evidence base. That part is accurate. There is no published RCT establishing the 25mg-twice-weekly subcutaneous protocol as optimal. It is largely consensus-based guidance from compounding pharmacies and clinical practice, not hard trial data.

Where he goes wrong is in the leap from "slow titration lacks evidence" to "therefore escalate fast." Fast escalation also lacks evidence. You cannot reject one unsupported protocol by replacing it with another unsupported protocol and call it science. That is not how it works.

His dismissal of NMN and NR as "garbage" is too blunt. These are not the same as injectable NAD+, but calling them ineffective ignores a growing body of human trial data. Researchers like Charles Brenner, who developed nicotinamide riboside as a supplement, have published peer-reviewed work showing measurable NAD+ elevation from oral precursors.

He is also recommending what is effectively a self-directed loading protocol for a compound being injected without clinical monitoring. That is a meaningful safety gap, especially for people with cardiovascular conditions, where rapid NAD+ shifts can trigger palpitations and nausea even in clinical IV settings.

What should you actually know?

NAD+ injections are not FDA-approved as a drug for the uses discussed here. They are available through compounding pharmacies, which means formulation, purity, and concentration can vary. The clinical IV NAD+ protocols used in addiction treatment are administered under medical supervision for a reason: side effects at higher doses include nausea, chest tightness, and flushing.

If you are considering NAD+ therapy, the most responsible starting point is a conversation with a licensed clinician who can review your health history. The energy benefits some people report are real, but individual response varies significantly, and there is no published data telling you what dose or schedule is right for any particular person.

• NAD+ levels do decline with age, and this has been replicated in multiple human studies.
• IV NAD+ loading protocols exist in clinical settings but are administered with monitoring.
• Oral NMN and NR do raise NAD+ levels in humans, per recent RCT data, even if the magnitude differs from injectable routes.
• Subcutaneous NAD+ pharmacokinetics have not been rigorously studied in published literature.
• Rapid self-directed dose escalation without clinical oversight carries real risks that this video does not adequately address.